Abstract
Patients with COVID-19 often have coagulation disorders and elevated D-dimer levels. The same changes are also typical for cancer patients. The standard anticoagulation therapy for these patients is the use of low-molecular-weight heparin, which in rare cases may cause heparin-induced thrombocytopenia (HIT), a serious complication associated with paradoxical autoimmune reactions to heparin. This article presents a clinical case of HIT against the background of severe COVID-19 in a patient with ovarian cancer. Key words: heparin-induced thrombocytopenia, coronavirus infection, COVID-19, low-molecular-weight heparin, thrombotic complications, thrombocytopenia, ovarian cancer
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
